Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have received a high-dose chemotherapy drug called melphalan (at a dose of 140–200 mg/m²)
- People who have undergone an autologous stem cell transplant (a transplant using their own stem cells)
Who may not be able to join:
- People who have a known allergy to the medication olanzapine
- People who have had nausea or vomiting in the 24 hours before enrolling in the trial
- People who have used certain other antipsychotic medications — such as risperidone, quetiapine, clozapine, or related drug types — within the 30 days before enrolling, or who plan to use them during the trial
- People with chronic alcoholism
- People who are pregnant
- People who are unwilling or unable to give informed consent to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 706-721-6493
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete Response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.